Skip to main content

Market Overview

Dr. Reddy's Stock Is Trading Higher As Sputnik V Vaccine Gets Emergency Use Nod In India: Report

Share:
Dr. Reddy's Stock Is Trading Higher As Sputnik V Vaccine Gets Emergency Use Nod In India: Report
  • The panel of India’s Central Drugs Standard Control Organization (CDSCO) has recommended the emergency use authorization of Russia’s Sputnik V coronavirus vaccine, said two people familiar with the matter.
  • The approval makes it the third such shot approved by India as the country is battling with a record daily surge in COVID-19 infections.
  • Neither Dr. Reddy’s Laboratories Ltd (NYSE: RDY), which markets the vaccine in India, nor the drugs regulator, responded immediately to Reuters’ requests for comment.
  • Sputnik V, developed by Moscow’s Gamaleya Institute, has proved 91.6% effective against COVID-19 and has been approved for use in more than 50 countries.
  • The Russian Direct Investment Fund has signed deals to produce more than 750 million doses of Sputnik V in India with six domestic firms.
  • The vaccine gained international recognition in February, overcoming early skepticism.
  • After peer-reviewed results were published in The Lancet medical journal, countries are lining up for supplies, reported Bloomberg.
  • Price Action: RDY shares are up 3.8% at $66.36 on the last check Monday.
 

Related Articles (RDY)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 VaccineBiotech Government News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com